FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015294539> ?p ?o ?g. }

• W2015294539 endingPage "856" @default.
• W2015294539 startingPage "850" @default.
• W2015294539 abstract "Nanoparticle albumin-bound paclitaxel, a solvent-free, albumin-bound paclitaxel, demonstrated antitumor activity in patients with taxane-naive metastatic breast cancer (MBC). We examined albumin-bound paclitaxel (100 mg/m2 or 125 mg/m2 administered weekly) to determine the antitumor activity in patients with MBC whose disease progressed despite conventional taxane therapy.Women with MBC that was previously treated with taxanes were eligible for participation. Taxane failure was defined as metastatic disease progression during taxane therapy or relapse within 12 months of adjuvant taxane therapy. Primary objectives were response rates (RRs) and the safety/tolerability of albumin-bound paclitaxel.Women were treated with albumin-bound paclitaxel 100 mg/m2 (n = 106) or 125 mg/m2 (n = 75) on days 1, 8, and 15 of a 28-day cycle. Response rates were 14% and 16% for the 100-mg/m2 and 125-mg/m2 cohorts, respectively; an additional 12% and 21% of patients, respectively, had stable disease (SD) > or = 16 weeks. Median progression-free survival times were 3 months at 100 mg/m2 and 3.5 months at 125 mg/m2; median survival times were 9.2 months and 9.1 months, respectively. Survival was similar for responding patients and those with SD. No severe hypersensitivity reactions were reported. Patients who developed treatment-limiting peripheral neuropathy typically could be restarted on a reduced dose of albumin-bound paclitaxel after a 1-2-week delay. Grade 4 neutropenia occurred in < 5% of patients.Albumin-bound paclitaxel 100 mg/m2 given weekly demonstrated the same antitumor activity as albumin-bound paclitaxel 125 mg/m2 weekly and a more favorable safety profile in patients with MBC that had progressed with previous taxane therapy. Survival of patients with SD > or = 16 weeks was similar to that of responders." @default.
• W2015294539 created "2016-06-24" @default.
• W2015294539 creator A5003827285 @default.
• W2015294539 creator A5010188774 @default.
• W2015294539 creator A5028702563 @default.
• W2015294539 creator A5035814482 @default.
• W2015294539 creator A5040949476 @default.
• W2015294539 creator A5042123072 @default.
• W2015294539 creator A5059365988 @default.
• W2015294539 creator A5071432873 @default.
• W2015294539 creator A5075481530 @default.
• W2015294539 date "2007-12-01" @default.
• W2015294539 modified "2023-10-06" @default.
• W2015294539 title "Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes" @default.
• W2015294539 cites W1885306047 @default.
• W2015294539 cites W1939003096 @default.
• W2015294539 cites W1946759281 @default.
• W2015294539 cites W2078775260 @default.
• W2015294539 cites W2139248078 @default.
• W2015294539 cites W2144536924 @default.
• W2015294539 cites W2153017356 @default.
• W2015294539 cites W2155808778 @default.
• W2015294539 cites W2164934025 @default.
• W2015294539 doi "https://doi.org/10.3816/cbc.2007.n.049" @default.
• W2015294539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18269774" @default.
• W2015294539 hasPublicationYear "2007" @default.
• W2015294539 type Work @default.
• W2015294539 sameAs 2015294539 @default.
• W2015294539 citedByCount "157" @default.
• W2015294539 countsByYear W20152945392012 @default.
• W2015294539 countsByYear W20152945392013 @default.
• W2015294539 countsByYear W20152945392014 @default.
• W2015294539 countsByYear W20152945392015 @default.
• W2015294539 countsByYear W20152945392016 @default.
• W2015294539 countsByYear W20152945392017 @default.
• W2015294539 countsByYear W20152945392018 @default.
• W2015294539 countsByYear W20152945392019 @default.
• W2015294539 countsByYear W20152945392020 @default.
• W2015294539 countsByYear W20152945392021 @default.
• W2015294539 countsByYear W20152945392022 @default.
• W2015294539 countsByYear W20152945392023 @default.
• W2015294539 crossrefType "journal-article" @default.
• W2015294539 hasAuthorship W2015294539A5003827285 @default.
• W2015294539 hasAuthorship W2015294539A5010188774 @default.
• W2015294539 hasAuthorship W2015294539A5028702563 @default.
• W2015294539 hasAuthorship W2015294539A5035814482 @default.
• W2015294539 hasAuthorship W2015294539A5040949476 @default.
• W2015294539 hasAuthorship W2015294539A5042123072 @default.
• W2015294539 hasAuthorship W2015294539A5059365988 @default.
• W2015294539 hasAuthorship W2015294539A5071432873 @default.
• W2015294539 hasAuthorship W2015294539A5075481530 @default.
• W2015294539 hasConcept C121608353 @default.
• W2015294539 hasConcept C126322002 @default.
• W2015294539 hasConcept C143998085 @default.
• W2015294539 hasConcept C197934379 @default.
• W2015294539 hasConcept C2775930923 @default.
• W2015294539 hasConcept C2776125364 @default.
• W2015294539 hasConcept C2776694085 @default.
• W2015294539 hasConcept C2777063308 @default.
• W2015294539 hasConcept C2777292972 @default.
• W2015294539 hasConcept C2777511904 @default.
• W2015294539 hasConcept C2778375690 @default.
• W2015294539 hasConcept C2781190966 @default.
• W2015294539 hasConcept C530470458 @default.
• W2015294539 hasConcept C71924100 @default.
• W2015294539 hasConcept C90924648 @default.
• W2015294539 hasConceptScore W2015294539C121608353 @default.
• W2015294539 hasConceptScore W2015294539C126322002 @default.
• W2015294539 hasConceptScore W2015294539C143998085 @default.
• W2015294539 hasConceptScore W2015294539C197934379 @default.
• W2015294539 hasConceptScore W2015294539C2775930923 @default.
• W2015294539 hasConceptScore W2015294539C2776125364 @default.
• W2015294539 hasConceptScore W2015294539C2776694085 @default.
• W2015294539 hasConceptScore W2015294539C2777063308 @default.
• W2015294539 hasConceptScore W2015294539C2777292972 @default.
• W2015294539 hasConceptScore W2015294539C2777511904 @default.
• W2015294539 hasConceptScore W2015294539C2778375690 @default.
• W2015294539 hasConceptScore W2015294539C2781190966 @default.
• W2015294539 hasConceptScore W2015294539C530470458 @default.
• W2015294539 hasConceptScore W2015294539C71924100 @default.
• W2015294539 hasConceptScore W2015294539C90924648 @default.
• W2015294539 hasIssue "11" @default.
• W2015294539 hasLocation W20152945391 @default.
• W2015294539 hasLocation W20152945392 @default.
• W2015294539 hasOpenAccess W2015294539 @default.
• W2015294539 hasPrimaryLocation W20152945391 @default.
• W2015294539 hasRelatedWork W1980931076 @default.
• W2015294539 hasRelatedWork W1990296886 @default.
• W2015294539 hasRelatedWork W2000433012 @default.
• W2015294539 hasRelatedWork W2046196715 @default.
• W2015294539 hasRelatedWork W2065556081 @default.
• W2015294539 hasRelatedWork W2101100140 @default.
• W2015294539 hasRelatedWork W2132924838 @default.
• W2015294539 hasRelatedWork W2509022872 @default.
• W2015294539 hasRelatedWork W2513994891 @default.
• W2015294539 hasRelatedWork W4220948627 @default.
• W2015294539 hasVolume "7" @default.
• W2015294539 isParatext "false" @default.

• next